Overview

Gender

male

Mr. Schade has more than 30 years of extensive private and public pharmaceutical and biotechnology industry experience as well as broad capital markets experience from his tenure in the investment banking industry. Prior to joining Novira he was Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals (NASDAQ: OMTH) where he played a lead role in taking the company public and in the sale of the company to AstraZeneca Plc., which closed in July 2013.

Prior to joining Omthera, Mr. Schade was Executive Vice President and Chief Financial Officer at NRG Energy (NYSE: NRG). From 2000 to 2009 he was Senior Vice President of Administration and Chief Financial Officer at Medarex (NASDAQ: MEDX), a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders and infectious diseases. Mr. Schade played a pivotal role in the acquisition of Medarex by Bristol Myers Squibb, leading the negotiations for the sale and merger-integration process of the research, development and administrative functions during this process.

Before joining Medarex, Mr. Schade served as Managing Director at Merrill Lynch in London, where he was head of the European Corporate Funding Group and was responsible for certain capital markets activities for Merrill Lynch’s European corporate clients. Additionally, he held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co.

Mr. Schade received an MBA from the Wharton School at the University of Pennsylvania and a Bachelor of Arts in History from Princeton University. Mr. Schade currently serves as Chairman of the Board of Trustees of Princeton Academy of the Sacred Heart, and also serves on the Board of Directors at Integra Life Sciences (NASDAQ: IART).